Clinical trialNCT04198766RecruitingPhase 1/PHASE2Interventional

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

SponsorInhibrx Biosciences, IncEnrollment340Gastric CancerHead and Neck CancerMelanomaNon-Small Cell Lung CancerRenal Cell CarcinomaResectable Non-Small-Cell Lung Cancer+2 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp \& Dohme LLC, a subsidiary of Merck \& Co., Inc., Rahway, NJ, USA.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Clinical Lead
Inhibrx Biosciences, Inc
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

42 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Singapore

Curie Oncology
Singapore, Singapore
Completed
Icon Cancer Centre Farrer Park
Singapore, Singapore
Completed
Icon Cancer Centre Mount Alvernia
Singapore, Singapore
Completed

South Korea

the Catholic University of Korea, St. Vincent'S Hospital
Gyeonggi-do, South Korea
Active, not recruiting
Asan Medical Center
Seoul, South Korea
Active, not recruiting
Severance Hospital, Yonsei University Health System
Seoul, South Korea
Active, not recruiting
the Catholic University of Korea Seoul St. Mary'S Hospital,
Seoul, South Korea
Active, not recruiting

Taiwan

Changhua Christian Hospital (cch)
Changhua, Taiwan
Active, not recruiting
E-Da Cancer Hospital
Kaohsiung City, Taiwan
Active, not recruiting
Kaohsiung Medical University Chung-Ho Memorial Hospital (kmuh)
Kaohsiung City, Taiwan
Active, not recruiting
National Cheng Kung University Hospital
Tainan, Taiwan
Active, not recruiting
Taipei Veterans General Hospital
Taipei, Taiwan
Completed

United States

City of Hope
Duarte, California, United States
Aditya Shreenivas, MD
Recruiting
Los Angeles Cancer Network
Glendale, California, United States
Sungwon Kyung, MD
Recruiting
California Research Institute
Los Angeles, California, United States
Ghassan Al-Jazayrly, MD
Recruiting
Valkyrie Clinical Trials
Los Angeles, California, United States
David Berz, MD
Recruiting
Valkyrie Clinical Trials
Murrieta, California, United States
David Berz, MD
Recruiting
Providence Medical Foundation
Santa Rosa, California, United States
Ian Anderson, MD
Recruiting
Clermont Oncology Center
Clermont, Florida, United States
Gopal Kunta, MD
Recruiting
Mid Florida Hematology and Oncology Center
Orange City, Florida, United States
Santosh Nair, MD
Recruiting
Winship Cancer Institute - Emory University
Atlanta, Georgia, United States
Conor Steuer, MD
Recruiting
the University of Chicago Medical Center
Chicago, Illinois, United States
Active, not recruiting
University of Iowa
Iowa City, Iowa, United States
Active, not recruiting
Norton Cancer Institute
Louisville, Kentucky, United States
John Hamm, MD
Recruiting
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States
Completed
Henry Ford Cancer Institute
Detroit, Michigan, United States
Amy Weise, MD
Recruiting
Start Midwest
Grand Rapids, Michigan, United States
Active, not recruiting
Healthpartners Cancer Research Center
Saint Louis Park, Minnesota, United States
Active, not recruiting
Healthpartners Cancer Research Center (regions Hospital)
Saint Paul, Minnesota, United States
Completed
Intermountain Health Cancer Centers of Montana
Billings, Montana, United States
Completed
Nebraska Cancer Specialists
Omaha, Nebraska, United States
Ralph Hauke, MD
Recruiting
Montefiore Medical Center
The Bronx, New York, United States
Active, not recruiting
Cleveland Clinic
Cleveland, Ohio, United States
Active, not recruiting
Providence Portland Medical Center
Portland, Oregon, United States
Active, not recruiting
Vanderbilt University School of Medicine
Nashville, Tennessee, United States
Active, not recruiting
Sarah Cannon Research Institute at Mary Crowley
Dallas, Texas, United States
Completed
Renovatio Clinical - El Paso
El Paso, Texas, United States
Completed
Next Oncology
San Antonio, Texas, United States
Completed
Renovatio Clinical
The Woodlands, Texas, United States
Completed
the University of Texas Health Science Center at Tyler
Tyler, Texas, United States
Erminia Massarelli, MD, PhD, MS
Recruiting

2 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Carboplatin AUC-5Carboplatin AUC-6Cisplatin →Gemcitabine →INBRX-106 - Hexavalent OX40 agonist antibodyPaclitaxel →Pemetrexed →Pembrolizumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 10 Dec 2019
Primary completion: 31 Jul 2033
Completion: 31 Jul 2033
Last update posted: 29 Jul 2026
Registered enrollment: 340
Registry id: NCT04198766

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.